<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Results from the first-in-human phase I trial of the anti-programmed <z:hpo ids='HP_0011420'>death</z:hpo>-1 (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-1) antibody BMS-936558 in patients with treatment-refractory <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e>, including safety, tolerability, pharmacodynamics, and immunologic correlates, have been previously reported </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we provide long-term follow-up on three patients from that trial who sustained objective <z:mp ids='MP_0010537'>tumor regressions</z:mp> off therapy, and test the hypothesis that reinduction therapy for late <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> recurrence can be effective </plain></SENT>
<SENT sid="2" pm="."><plain>EXPERIMENTAL DESIGN: Three patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, <z:e sem="disease" ids="C0007134" disease_type="Neoplastic Process" abbrv="">renal cell cancer</z:e>, and <z:hpo ids='HP_0002861'>melanoma</z:hpo> achieved objective responses on an intermittent dosing regimen of BMS-936558 </plain></SENT>
<SENT sid="3" pm="."><plain>Following cessation of therapy, patients were followed for more than 3 years </plain></SENT>
<SENT sid="4" pm="."><plain>A patient with <z:hpo ids='HP_0002861'>melanoma</z:hpo> who experienced a prolonged partial regression followed by <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> recurrence received reinduction therapy </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: A patient with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> experienced a complete response, which is ongoing after 3 years </plain></SENT>
<SENT sid="6" pm="."><plain>A patient with <z:e sem="disease" ids="C0007134" disease_type="Neoplastic Process" abbrv="">renal cell cancer</z:e> experienced a partial response lasting 3 years off therapy, which converted to a complete response, which is ongoing at 12 months </plain></SENT>
<SENT sid="7" pm="."><plain>A patient with <z:hpo ids='HP_0002861'>melanoma</z:hpo> achieved a partial response that was stable for 16 months off therapy; <z:e sem="disease" ids="C0277556" disease_type="Disease or Syndrome" abbrv="">recurrent disease</z:e> was successfully treated with reinduction anti-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-1 therapy </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: These data represent the most prolonged observation to date of patients with <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> responding to anti-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-1 immunotherapy and the first report of successful reinduction therapy following delayed <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>They underscore the potential for immune checkpoint blockade with anti-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-1 to reset the equilibrium between <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> and the host immune system </plain></SENT>
</text></document>